Drug interactions
Gemcitabine + Tisagenlecleucel
Severity: Major
Gemcitabine and Tisagenlecleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Gemcitabine causes myelosuppression and tisagenlecleucel can cause prolonged cytopenias and B-cell aplasia. Combining them increases infection risk and may compromise CAR-T cell collection or expansion.
What this interaction means in plain words
Gemcitabine and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Gemcitabine belongs to Oncology; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive immunosuppression and myelosuppression; cytotoxic therapy may impair CAR-T cell function and expansion.
What to do
Avoid chemotherapy in the washout period before leukapheresis and around infusion apart from planned lymphodepletion. Monitor blood counts and infection if chemotherapy is later needed.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Gemcitabine and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Gemcitabine
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Gemcitabine with Tisagenlecleucel?
MediHelp rates the interaction as major. Gemcitabine and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Gemcitabine causes myelosuppression and tisagenlecleucel can cause prolonged cytopenias and B-cell aplasia. Combining them increases infection risk and may compromise CAR-T cell collection or expansion.
How serious is the interaction between Gemcitabine and Tisagenlecleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid chemotherapy in the washout period before leukapheresis and around infusion apart from planned lymphodepletion. Monitor blood counts and infection if chemotherapy is later needed.
What other medicines interact with Gemcitabine?
MediHelp also lists interactions of Gemcitabine with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Belatacept. The full list is on the Gemcitabine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
